Compare ZDGE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | VERU |
|---|---|---|
| Founded | 2008 | 1971 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 44.0M |
| IPO Year | 2016 | 1996 |
| Metric | ZDGE | VERU |
|---|---|---|
| Price | $3.01 | $2.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 65.7K | ★ 202.3K |
| Earning Date | 06-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ 73.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,398,000.00 | $16,296,958.00 |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.21 | $2.05 |
| 52 Week High | $4.70 | $7.33 |
| Indicator | ZDGE | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 36.57 |
| Support Level | $2.88 | $2.12 |
| Resistance Level | $3.15 | $2.40 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 37.93 | 1.79 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.